Overall, the P4-LMP1-IFN-γ/p-JNK-BTN2A1/BTN3A1 axis identified by these experiments likely underlie the effectiveness of the P4 plus PTA-Vδ2 T cell therapy against NPC. The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.